MCK vs SOLV: fair value comparison
McKesson Corporation and Solventum Corporation · Updated 2026-09-12
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, MCK currently sits closer to the top of our discount ranking.
| MCK | SOLV | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $881.51 | $87.45 |
| 12-month range | $734.82–$990.95 | $64.35–$90.95 |
| Sector rank | #79 of 113 Healthcare | #81 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: MCK fair value analysis · SOLV fair value analysis